Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Dr. Stephen Finn

Associate Professor Consultant (Histopathology)


Dr. Stephen Finn MB BAO BCh FDS PhD FRCPath FFPATH, is a Associate Professor, Consultant Pathologist and Principal Investigator at The University of Dublin, Trinity College and at St. James's Hospital Dublin, a tertiary referral cancer institution. He is co-director of the Cancer Molecular Diagnostic Laboratory, the only fully accredited molecular diagnostic laboratory in Ireland. His clinical practice is limited to Urological, Gastrointestinal and Liver pathology. Dr. Finn is former Senior Scientist and Staff Pathologist to the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute, Boston, USA. Dr. Finn continues to have strong personal and collaborative links to the Harvard School of Public Health, the Dana Farber Cancer Institute and the University of Orebro in Sweden. Dr. Finn is a member of the Irish Prostate Cancer Research Consortium (PCRC) and the Transdisciplinary Prostate Cancer Partnership ToPCaP. Dr. Finn, a current recipient of the Prostate Cancer Foundation Young investigator Award, and is committed to forging a career as an independent researcher focused on prostate cancer and bringing his skills as a clinician, pathologist and scientist to bear on critical questions of clinical relevance to men who suffer from aggressive prostate cancer.
 Identifying non-coding RNA repertoires of aggressive Prostate cancer
 EXPECT Trial: Evasion of immune editing by circulating tumour cells is an exercise-modifiable mechanism underlying aggressive behaviour in obese men with prostate cancer
 Discovery and Clinical Implementation of Novel Predictive Biomarkers for Enzalutamide therapy

Details Date
Chairman Molecular Pathology, Faculty of Pathology, RCPI 01/02/2011
Details Date From Date To
Fellow of the Royal College of Pathologists 2005 Current
MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, Lung cancer stem cells: The root of resistance., 2016, Journal Article, PUBLISHED
Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG, KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma., International Journal of Oncology, 48, (3), 2016, p1290-1296 , Journal Article, PUBLISHED  DOI
Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA, Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression., 2016, Journal Article, PUBLISHED
Staunton, L., Tonry, C., Lis, R., Finn, S., O'Leary, J., Loda, M., Bowden, M., Pennington, S.R., Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC-MS-A technical report, EuPA Open Proteomics, 10, 2016, p19-23 , Journal Article, PUBLISHED
Leon, G., MacDonagh, L., Finn, S.P., Cuffe, S., Barr, M.P., Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways, Pharmacology and Therapeutics, 2016, Journal Article, PUBLISHED
Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG, KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma., International journal of oncology, 48, (3), 2016, p1290-6 , Journal Article, PUBLISHED  DOI
Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL, A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer., Journal of the National Cancer Institute, 108, (2), 2015, Journal Article, PUBLISHED  DOI
van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients., 2015, Journal Article, PUBLISHED
Rider, J.R., Fiorentino, M., Kelly, R., Gerke, T., Jordahl, K., Sinnott, J.A., Giovannucci, E.L., Loda, M., Mucci, L.A., Finn, S., Tumor expression of adiponectin receptor 2 and lethal prostate cancer, Carcinogenesis, 36, (6), 2015, p639-647 , Journal Article, PUBLISHED
MacDonagh,Lauren , Gray,Steven George, Finn,Stephen P. , Cuffe,Sinead D. , O'Byrne,Kenneth John, Barr,Martin P. , The emerging role of microRNAs in resistance to lung cancer treatments, Cancer Treatment Reviews, 41, (2), 2015, p160-169 , Journal Article, PUBLISHED  DOI

Page 1 of 11